BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37544710)

  • 1. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.
    Miller RJ; Mousa JJ
    Curr Opin Virol; 2023 Aug; 61():101337. PubMed ID: 37544710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.
    Huang J; Miller RJ; Mousa JJ
    Front Immunol; 2022; 13():941865. PubMed ID: 36003370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode.
    Wen X; Suryadevara N; Kose N; Liu J; Zhan X; Handal LS; Williamson LE; Trivette A; Carnahan RH; Jardetzky TS; Crowe JE
    Cell Host Microbe; 2023 Aug; 31(8):1288-1300.e6. PubMed ID: 37516111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Epitopes of Pneumovirus Fusion Proteins.
    Huang J; Diaz D; Mousa JJ
    Front Immunol; 2019; 10():2778. PubMed ID: 31849961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus
    Bar-Peled Y; Diaz D; Pena-Briseno A; Murray J; Huang J; Tripp RA; Mousa JJ
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling of hMPV F-specific antibodies isolated from human memory B cells.
    Xiao X; Fridman A; Zhang L; Pristatsky P; Durr E; Minnier M; Tang A; Cox KS; Wen Z; Moore R; Tian D; Galli JD; Cosmi S; Eddins MJ; Sullivan NL; Yan X; Bett AJ; Su HP; Vora KA; Chen Z; Zhang L
    Nat Commun; 2022 May; 13(1):2546. PubMed ID: 35538099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.
    Schuster JE; Cox RG; Hastings AK; Boyd KL; Wadia J; Chen Z; Burton DR; Williamson RA; Williams JV
    J Infect Dis; 2015 Jan; 211(2):216-25. PubMed ID: 24864121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
    Kinder JT; Moncman CL; Barrett C; Jin H; Kallewaard N; Dutch RE
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32759319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.
    Mousa JJ; Binshtein E; Human S; Fong RH; Alvarado G; Doranz BJ; Moore ML; Ohi MD; Crowe JE
    PLoS Pathog; 2018 Feb; 14(2):e1006837. PubMed ID: 29470533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
    Wen X; Mousa JJ; Bates JT; Lamb RA; Crowe JE; Jardetzky TS
    Nat Microbiol; 2017 Jan; 2():16272. PubMed ID: 28134915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.
    Bates JT; Pickens JA; Schuster JE; Johnson M; Tollefson SJ; Williams JV; Davis NL; Johnston RE; Schultz-Darken N; Slaughter JC; Smith-House F; Crowe JE
    Vaccine; 2016 Feb; 34(7):950-6. PubMed ID: 26772634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
    Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes.
    Xiao X; Tang A; Cox KS; Wen Z; Callahan C; Sullivan NL; Nahas DD; Cosmi S; Galli JD; Minnier M; Verma D; Babaoglu K; Su H; Bett AJ; Vora KA; Chen Z; Zhang L
    MAbs; 2019; 11(8):1415-1427. PubMed ID: 31402751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protective antibodies against common endemic respiratory viruses.
    Cabán M; Rodarte JV; Bibby M; Gray MD; Taylor JJ; Pancera M; Boonyaratanakornkit J
    Nat Commun; 2023 Feb; 14(1):798. PubMed ID: 36781872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV.
    Wen X; Pickens J; Mousa JJ; Leser GP; Lamb RA; Crowe JE; Jardetzky TS
    PLoS One; 2016; 11(5):e0155917. PubMed ID: 27224013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.